hepat
c
viru
hcv
infect
affect
estim
million
individu
worldwid
contribut
signific
morbid
mortal
rate
associ
liver
cirrhosi
hepatocellular
carcinoma
approxim
infect
individu
clear
viru
follow
acut
infect
develop
chronic
infect
lead
endstag
liver
diseas
complic
although
treatment
option
use
combin
pegyl
ribavirin
avail
sustain
clearanc
viru
achiev
approxim
individu
infect
hcv
genotyp
infect
genotyp
recent
advanc
treatment
hcv
use
directli
act
antivir
agent
daa
boceprevir
telaprevir
improv
svr
rate
treatment
experienc
patient
review
howev
treatment
prolong
expens
also
associ
substanti
side
effect
develop
effect
vaccin
significantli
reduc
number
new
infect
improv
sustain
virolog
respons
rate
could
therefor
use
adjunct
current
therapeut
approach
reduc
impact
infect
global
health
care
system
whilst
immun
correl
mediat
clearanc
viru
still
entir
clear
defin
substanti
evid
demonstr
develop
broad
multifunct
cell
respons
array
key
viral
protein
core
acut
hcv
infect
associ
diseas
resolut
may
also
provid
level
protect
reinfect
also
becom
increasingli
appar
respons
alon
enough
neutralis
antibodi
also
play
integr
role
confer
protect
facilit
viral
clearanc
mechan
includ
antibodydepend
cellular
cytotox
mechan
effect
hcv
vaccin
need
induc
antibodi
cellmedi
respons
also
provid
cross
protect
differ
viral
genotyp
quasispeci
neutralis
antibodi
induc
conserv
conform
epitop
viral
envelop
glycoprotein
notabl
antigen
region
includ
critic
neutralis
contact
residu
contain
within
domain
amino
acid
broadli
crossneutralis
fact
antibodi
neutralis
differ
hcv
genotyp
highlight
import
includ
epitop
envelop
protein
vaccin
strategi
effect
viruslik
particl
vlp
possess
featur
make
ideal
vehicl
deliveri
viral
antigen
immun
system
antibodi
epitop
present
nativ
conform
induct
potenti
neutralis
antibodi
ii
multipl
cell
epitop
packag
vlp
iii
vlp
lack
regulatori
protein
well
genet
materi
could
pose
risk
revers
mutat
iv
encourag
result
obtain
use
insect
cellderiv
recombin
vlp
express
hcv
antigen
induc
virusspecif
humor
cellular
respons
v
hcv
vlp
appear
possess
properti
favour
dendrit
cell
uptak
vi
exhibit
superior
immunogen
antigen
recombin
protein
dnabas
vaccin
approach
import
consider
manufactur
hcvbase
vlp
celltyp
use
manufactur
exampl
shown
vaccin
recombin
hcv
envelop
protein
express
mammalian
cell
yeast
insect
cell
protect
chimpanze
primari
infect
homolog
hcv
isol
similarli
rosa
et
al
demonstr
mammalian
cellderiv
recombin
envelop
protein
bind
human
cell
higher
affin
produc
yeast
insect
cell
appear
antigen
function
similar
viral
protein
produc
infect
host
cell
recent
vaccin
macaqu
use
vlp
primeboost
regim
report
induc
broadli
neutralis
antibodi
respons
differ
hcv
genotyp
although
studi
provid
encourag
result
support
develop
hcv
vlpbase
vaccin
fact
heterolog
viral
vector
andor
unrealist
dose
regim
requir
induc
protect
immun
indic
necessari
improv
immunogen
studi
evalu
immunogen
mammalian
cellderiv
vlp
contain
structur
protein
core
hcv
genotyp
deliv
directli
dendrit
cell
dc
use
tolllik
receptor
target
lipopeptid
lipopeptid
contain
agonist
dipalmitoylsglycerylcystein
associ
electrostat
protein
antigen
significantli
improv
abil
induc
humor
cellmedi
respons
abil
lipopeptidevlp
complex
facilit
dc
uptak
induc
antibodi
capabl
inhibit
vlp
entri
target
cell
elicit
cellmedi
antigenspecif
respons
determin
hcv
viruslik
particl
construct
use
recombin
adenoviru
contain
encod
hcv
structur
protein
core
hcv
genotyp
briefli
gene
amplifi
pbrtmhcv
plasmid
contain
genom
hcv
genotyp
gift
prof
c
rice
gene
amplifi
pbrtmhcv
plasmid
contain
genom
hcv
genotyp
gift
prof
c
rice
forward
primer
design
introduc
xbai
enzym
restrict
site
follow
kozak
sequenc
start
codon
tag
amino
termin
end
core
protein
revers
primer
ggcttaagcccggtgacgtgggtttcc
gcgtcgac
design
amplifi
sequenc
downstream
region
correspond
cleavag
site
amino
acid
introduc
afl
ii
restrict
site
end
next
genom
amplifi
use
forward
primer
also
introduc
spei
site
end
revers
primer
gcctccgcttgggatatgagtaacatcatcc
design
introduc
doubl
stop
codon
ecorv
restrict
site
end
amplicon
amplicon
clone
pgemeasi
promega
subsequ
subclon
ligat
produc
construct
verifi
dna
sequenc
construct
subsequ
subclon
padtrackcmv
provid
b
vogelstein
howard
hugh
medic
centr
baltimor
digest
pmei
transform
cell
electropor
biorad
gene
pulser
previous
describ
high
titr
recombin
adenovirion
encod
hcv
protein
produc
cell
serial
passag
equival
multipl
infect
moi
determin
describ
previous
produc
hcv
vlp
cell
infect
moi
hour
postinfect
cell
collect
disrupt
use
dounc
homogenis
centrifug
g
min
supernat
centrifug
sucros
cushion
contain
mm
tri
ph
mm
nacl
g
hour
result
pellet
resuspend
mm
tri
ph
mm
nacl
purifi
caesium
chlorid
gradient
ultracentrifug
g
hour
twelv
ml
gradient
recov
dialys
steril
pb
overnight
fluoresc
label
vlp
achiev
ad
vlp
mgml
mgml
fluorescein
isothiocyan
fitc
sigma
aldrich
dmso
suspens
vortex
vigor
incub
overnight
dialysi
pb
next
day
vlp
prepar
store
aliquot
use
cell
grown
dulbecco
modifi
eagl
medium
dmem
invitrogen
usa
supplement
fetal
calf
serum
fc
streptomycin
c
synthes
branch
anion
peptid
construct
contain
eight
ntermin
glutam
acid
residu
use
tradit
fmoc
chemistri
describ
previous
briefli
synthesi
carri
manual
use
peg
ram
solid
support
rapp
polymer
germani
substitut
factor
mmolg
fmoclysin
mtt
oh
novabiochem
switzerland
first
coupl
support
fmoc
protect
group
present
group
remov
fmoclysin
fmoc
oh
coupl
expos
ntermin
amino
group
subsequ
deprotect
acyl
anoth
two
round
fmoclysin
fmoc
oh
yield
eight
branch
point
glutam
acid
residu
coupl
primari
amino
group
glutam
acid
residu
acetyl
use
excess
acet
anhydrid
excess
diisopropylethylamin
dipea
sigma
australia
gener
overal
charg
lipid
carri
remov
mtt
protect
group
present
group
ctermin
lysin
follow
acyl
expos
group
two
serial
ad
serin
residu
lipid
moieti
coupl
accord
zeng
et
al
gener
figur
follow
assembl
lipopeptid
cleav
solid
phase
support
sidechain
protect
group
remov
tfa
phenol
tip
water
hour
room
temperatur
lipopeptid
analys
revers
phase
highpressur
liquid
chromatographi
rphplc
use
vydac
column
mm
instal
water
hplc
system
chromatogram
develop
flow
rate
mlmin
use
tfa
tfa
acetonitril
limit
solvent
lipopeptid
purifi
necessari
product
present
singl
major
peak
analyt
rphplc
expect
mass
analys
use
agil
seri
ion
trap
mass
spectromet
line
murin
balbcderiv
dc
cell
prepar
propag
accord
method
describ
chua
et
al
minimum
day
cultur
cell
stain
class
ii
mhc
use
fitc
conjug
antiiai
antibodi
clone
becton
dickinson
usa
peconjug
clone
becton
dickinson
usa
prior
use
cell
verifi
class
ii
flow
cytometri
use
facscalib
becton
dickinson
usa
cell
seed
onto
petri
dish
ml
fresh
media
incub
presenc
absenc
fitclabel
vlp
alon
vlp
mix
pmoleml
cell
harvest
hour
later
wash
fac
wash
mm
edta
pb
fixat
paraformaldehyd
pb
examin
cellular
associ
vlp
cell
fluoresc
analys
flow
cytometri
facscalib
becton
dickinson
usa
examin
intracellular
uptak
vlp
extracellular
fluoresc
quench
addit
equal
volum
citrat
buffer
ph
contain
trypan
blue
merck
damstadt
germani
prior
analysi
data
analys
use
flowjo
softwar
tree
star
san
carlo
ca
assess
degre
dc
matur
result
exposur
differ
adjuv
cell
expos
vari
concentr
aluminium
hydroxid
gel
alhydrogel
sigma
aldrich
missouri
usa
lipopolysaccharid
posit
control
lp
sigma
aldrich
milwauke
usa
experi
cell
incub
vlp
alon
presenc
hour
cell
harvest
wash
analys
express
surfac
class
ii
mhc
antigen
experiment
procedur
involv
anim
approv
univers
melbourn
anim
ethic
committe
aec
number
transgen
mice
hhd
mice
obtain
queensland
institut
medic
research
bred
anim
hous
facil
depart
microbiolog
immunolog
univers
melbourn
specif
pathogen
free
condit
mice
express
instead
express
chimer
monochain
domain
cytoplasm
transmembran
domain
link
nterminu
c
terminu
human
microglobulin
femal
hhd
mice
per
group
inocul
subcutan
side
base
tail
per
dose
vlp
either
alon
emulsifi
equal
volum
complet
freund
adjuv
cfa
equal
amount
day
spleen
remov
day
second
dose
splenocyt
restimul
vitro
concentr
cellsml
medium
consist
rpmi
medium
gibco
usa
supplement
fetal
calf
serum
csl
parkvil
australia
mm
hepe
mm
lglutamin
uml
penicillin
streptomycin
nonessenti
amino
acid
uml
recombin
roch
indianapoli
usa
atmospher
restimul
carri
presenc
vlp
irrelev
hcvderiv
epitop
contain
vlp
construct
cell
harvest
day
later
wash
serial
dilut
commenc
cellsml
perform
polyvinyliden
fluorid
pvdf
membranelin
plate
millipor
ireland
previous
coat
captur
antibodi
clone
pharmingen
san
diego
usa
cell
cultur
presenc
irradi
autolog
vlppuls
splenocyt
hour
wash
pbst
pb
contain
tween
biotinyl
detect
antibodi
clone
becton
dickinson
usa
ad
incub
hour
room
temperatur
humidifi
atmospher
plate
wash
streptavidinalkalin
phosphatas
becton
dickinson
usa
ad
incub
hour
spot
repres
cell
develop
addit
mgml
phosphat
buffer
sigmaaldrich
usa
minut
individu
spot
count
use
aid
ispot
elispot
reader
gmbh
strassberg
germani
analysi
varianc
experi
p
valu
studi
conduct
obtain
use
oneway
anova
nonparametr
statist
analysi
tukey
posthoc
rang
test
perform
prism
graphpad
softwar
la
jolla
california
usa
femal
week
old
balbc
mice
inocul
subcutan
side
base
tail
per
dose
day
either
vlp
alon
vlp
preincub
equal
volum
alhydrogel
mgml
addit
dose
formul
administ
mice
group
day
sera
prepar
blood
taken
day
flat
bottom
polyvinyl
plate
coat
either
purifi
hcv
vlp
recombin
protein
overnight
prior
coat
plate
hcv
vlp
well
preincub
galanthu
nivali
lectin
sigma
aldrich
australia
carbon
buffer
mm
mm
mm
nacl
minut
room
temperatur
follow
remov
antigen
bsa
mgml
pb
ad
plate
incub
hour
room
temperatur
wash
four
time
pbst
pb
contain
vv
sigma
aldrich
milwauke
usa
serial
dilut
sera
obtain
immunis
mice
ad
well
incub
humidifi
atmospher
overnight
wash
bound
antibodi
detect
use
horseradish
peroxidaseconjug
rabbit
antimous
igg
antibodi
dako
glostrup
denmark
conjunct
enzym
substrat
mm
acid
mm
citric
acid
contain
hydrogen
peroxid
reaction
stop
addit
naf
titer
antibodi
express
reciproc
highest
dilut
serum
requir
achiev
optic
densiti
detect
specif
antibodi
secret
cell
elispot
pvdf
membranelin
plate
mabtech
nacka
strand
sweden
coat
pb
contain
vlp
recombin
anti
igg
antibodi
overnight
plate
wash
time
pb
block
hour
use
rpmi
medium
gibco
usa
supplement
bsa
sigma
australia
well
empti
splenocyt
medium
ad
incub
hour
atmospher
spot
form
unit
repres
specif
antibodyproduc
cell
develop
previous
describ
detect
cell
except
biotinyl
antiigg
antibodi
streptavidinconjug
horseradish
peroxidas
mabtech
nacka
strand
sweden
use
detect
reagent
order
determin
inhibit
cell
entri
vlp
use
antibodi
present
sera
vaccin
anim
cell
first
incub
pb
fc
min
reduc
nonspecif
bind
antibodi
subsequ
ad
cell
wash
twice
resuspend
pb
fc
incub
fitclabel
vlp
hr
serial
dilut
sera
vaccin
nonvaccin
mice
ad
incub
hour
reaction
cell
ng
fitclabel
vlp
use
total
volum
end
incub
period
cell
wash
pb
fc
fix
bd
cytofix
becton
dickinson
usa
inhibit
vlp
entri
determin
flow
cytometri
analys
use
weasel
softwar
walter
eliza
hall
institut
melbourn
australia
sera
vaccin
mice
demonstr
decreas
specif
cellular
bind
compar
sera
mice
consid
contain
neutralis
antibodi
hcv
genotyp
vlp
produc
transduc
human
hepatocytederiv
cell
line
recombin
adenoviru
contain
encod
hcv
structur
protein
core
genotyp
produc
particl
harbour
antigen
resembl
virion
produc
infect
host
cell
essenti
role
dc
play
induct
humor
cellmedi
respons
first
examin
abil
spleenderiv
dc
line
cell
take
fluorescein
isothiocyanatelabel
hcv
vlp
fitcvlp
flow
cytometr
analysi
reveal
dc
incub
fitcvlp
exhibit
higher
whole
cell
fluoresc
intens
compar
untreat
dc
indic
presenc
cellassoci
vlp
figur
exposur
dc
vlp
premix
lipopeptid
also
result
higher
level
cell
fluoresc
compar
untreat
dc
percentag
fluorescen
cell
cultur
similar
cultur
contain
fitcvlp
alon
figur
determin
magnitud
vlp
cell
uptak
intracellular
fluoresc
measur
quench
extracellular
fluoresc
exposur
cell
trypan
blue
prior
flow
cytometr
analysi
although
result
fluoresc
intens
dc
incub
fitcvlp
lower
follow
treatment
level
still
notabl
higher
untreat
cell
confirm
presenc
intracellular
fitcvlp
figur
equival
fluoresc
cell
intens
also
observ
dc
incub
fitcvlp
premix
howev
higher
percentag
fluorescen
cell
detect
cultur
compar
expos
fitcvlp
alon
figur
indic
increas
uptak
construct
facilit
use
lipopeptid
investig
abil
hcv
vlp
caus
activ
dc
measur
express
surfac
mhc
class
ii
molecul
follow
incub
variou
antigen
result
figur
indic
untreat
dc
contain
two
popul
cell
mhc
class
iilow
mhc
class
iihigh
latter
compris
popul
analys
distribut
popul
affect
exposur
hcv
vlp
alon
incub
hcv
vlp
mix
caus
dramat
shift
distribut
mhc
class
ii
express
cell
cell
mhc
class
iihigh
upregul
mhc
class
ii
express
cell
compar
cultur
presenc
lp
potent
dc
matur
stimulu
dose
experi
show
increas
concentr
hcv
vlp
induc
dc
activ
percentag
mhc
class
iihigh
dc
cultur
contain
escal
dose
vlp
remain
similar
contain
untreat
dc
figur
contrast
exposur
littl
nmole
suffici
induc
greater
twofold
increas
activ
dc
compar
untreat
cell
figur
similar
level
activ
observ
lp
dc
activ
observ
presenc
alhydrogel
figur
presenc
hcv
vlpcontain
formul
howev
promot
uptak
hcv
vlp
dc
also
consider
increas
level
dc
activ
determin
dc
activ
properti
vlp
formul
contain
translat
improv
hcv
vlp
immunogen
balbc
mice
inocul
vlp
alon
vlp
mix
hcv
vlpspecif
antibodi
titr
sera
obtain
one
two
three
dose
formul
determin
elisa
administr
vlp
alon
salin
abl
elicit
detect
titr
specif
antibodi
margin
increas
dose
antigen
figur
anim
receiv
hcv
vlp
mix
howev
antibodi
level
significantli
higher
case
tenfold
anim
receiv
dose
hcv
vlp
alon
fact
titr
specif
antibodi
induc
follow
administr
dose
hcv
vlp
alon
achiev
use
singl
dose
hcv
vlp
mix
compar
anim
inocul
hcv
vlp
formul
alhydrogel
adjuv
wide
use
induc
antibodi
respons
human
veterinari
vaccin
lower
antibodi
titr
observ
anim
receiv
vlplipopeptid
formul
examin
level
specif
antibodi
elicit
vaccin
higher
titr
demonstr
anim
receiv
dose
vlp
mix
compar
inocul
vlp
alon
alhydrogel
figur
hierarch
pattern
antibodi
respons
induc
alhydrogel
also
confirm
number
specif
antibodi
secret
cell
detect
spleen
vaccin
mice
significantli
higher
number
cell
secret
hcv
vlp
figur
antibodi
figur
detect
anim
receiv
hcv
vlp
mix
inocul
hcv
vlp
alon
vlp
formul
alhydrogel
assess
neutralis
activ
antibodi
induc
vaccin
first
set
investig
vlp
entri
human
hepatocyt
cell
line
could
inhibit
preincub
fitclabel
vlp
vlpfitc
pb
serum
result
minim
inhibit
vlp
entri
figur
howev
presenc
antibodi
cell
surfac
molecul
implic
hcv
entri
hepatocyt
abl
prevent
vlp
entri
cell
confirm
vlp
also
utilis
molecul
facilit
cell
entri
next
analys
abil
sera
obtain
mice
inocul
vlp
inhibit
bind
entri
vlp
huh
cell
figur
neutralis
bind
vlp
cell
significantli
greater
sera
obtain
mice
inocul
vlp
compar
sera
obtain
mice
inocul
vlp
administ
alhydrogel
salin
abil
vlp
formul
contain
induc
cellmedit
immun
respons
examin
inocul
transgen
mice
express
mhc
class
allel
endogen
molecul
control
transgen
anim
inocul
vlp
alon
vlp
emulsifi
equal
amount
complet
freund
adjuv
cfa
splenocyt
vaccin
anim
obtain
day
postinocul
restimul
antigen
vitro
result
figur
elispot
assay
carri
reveal
significantli
higher
number
hcv
vlpspecif
produc
cell
spleen
mice
inocul
vlp
presenc
vlp
emulsifi
cfa
receiv
vlp
alon
develop
novel
effect
antivir
vaccin
strategi
recent
time
seen
notabl
shift
away
use
tradit
formul
util
whole
inactiv
live
attenu
virus
toward
approach
base
recombin
subunit
protein
antigen
easili
characteris
defin
vlp
offer
featur
make
use
platform
deliv
viral
antigen
singl
vaccin
construct
minimis
risk
may
associ
prepar
contain
requir
use
replic
pathogen
also
close
resembl
nativ
viral
antigen
deriv
convinc
demonstr
vlp
efficaci
quadrival
vlpbase
vaccin
gardasil
prevent
persist
infect
associ
diseas
caus
human
papillomaviru
studi
vlpbase
vaccin
strategi
also
shown
promis
result
led
phase
test
number
diseas
indic
includ
season
pandem
influenza
hepat
b
malaria
hiv
review
depend
type
viru
use
manufactur
vlp
construct
studi
shown
protect
respons
induc
vlp
elicit
without
coadministr
adjuv
mani
case
howev
induct
use
immun
respons
may
requir
multipl
dose
regim
may
impract
implement
field
involv
viral
vector
provid
initi
prime
dose
follow
boost
use
vlp
relev
present
studi
use
adjuv
enhanc
vlp
immunogen
shown
induc
strong
antibodi
respons
use
dosespar
amount
hiv
norwalk
virusderiv
vlp
also
elicit
cellmedi
respons
culmin
improv
protect
lethal
influenza
viral
tumorigen
challeng
previou
studi
shown
peptid
epitop
proteinbas
antigen
made
far
immunogen
coval
attach
order
target
deliveri
via
dendrit
cell
dc
result
induct
robust
antibodi
cellmedi
immun
respons
shown
multipl
indic
vaccin
candid
demonstr
abil
simpl
lipid
structur
dramat
enhanc
immunogen
antigen
otherwis
immunolog
inert
nevertheless
approach
introduc
complex
vaccin
manufactur
process
due
requir
coval
attach
antigen
use
anion
lipopeptid
overcom
mani
technic
complex
relat
process
especi
use
coval
chemistri
make
use
electrostat
associ
antigen
abil
dramat
enhanc
immunogen
hcv
vlp
demonstr
improv
overal
antibodi
respons
observ
greater
antibodi
titr
induc
follow
vaccin
vlp
formul
compar
use
vlp
alon
coadminist
alhydrogel
dose
nonadjuv
tradit
adjuv
antigen
requir
match
titr
obtain
singl
dose
use
lipopeptid
importantli
context
hcv
trend
translat
improv
antibodi
respons
use
lower
dose
vlp
achiev
maintain
efficaci
major
advantag
provid
cost
benefit
vaccin
manufactur
studi
examin
interact
vlp
dc
indic
improv
vlp
uptak
mediat
lipopeptid
minim
abil
concomitantli
induc
matur
dc
small
dose
featur
observ
use
vlp
alon
vlp
administ
presenc
alum
previou
work
also
demonstr
associ
antigen
charg
lipopeptid
facilit
traffick
antigen
lymph
node
drain
vaccin
site
togeth
result
present
studi
provid
explan
dosespar
neutralis
antibodi
respons
observ
coadministr
vlp
use
charg
lipopeptid
ad
benefit
elicit
vlpspecif
cellmedi
respons
transgen
mice
fact
may
also
attribut
dc
target
activ
given
result
work
describ
studi
conclud
use
branch
anion
lipopeptid
togeth
vlp
contain
hcv
antigen
order
provid
broad
spectrum
conform
epitop
provid
benefit
term
induc
improv
level
neutralis
antibodi
titr
elicit
cellmedi
respons
strategi
could
therefor
constitut
valuabl
addit
armamentarium
current
vlpbase
vaccin
develop
hcv
